Patents
Literature
22 results about "Protein L" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Protein L was first isolated from the surface of bacterial species Peptostreptococcus magnus and was found to bind immunoglobulins through L chain interaction, from which the name was suggested. It consists of 719 amino acid residues. The molecular weight of Protein L purified from the cell walls of Peptostreptoccus magnus was first estimated as 95kD by SDS-PAGE in the presence of reducing agent 2-mercaptoethanol, while the molecular weight was determined to 76kD by gel chromotography in the presence of 6 M guanidine HCl. Protein L does not contain any interchain disulfide loops, nor does it consist of disulfide-linked subunits. It is an acidic molecule with a pI of 4.0. Unlike Protein A and Protein G, which bind to the Fc region of immunoglobulins (antibodies), Protein L binds antibodies through light chain interactions. Since no part of the heavy chain is involved in the binding interaction, Protein L binds a wider range of antibody classes than Protein A or G. Protein L binds to representatives of all antibody classes, including IgG, IgM, IgA, IgE and IgD. Single chain variable fragments (scFv) and Fab fragments also bind to Protein L.
Glycan preparation method and glycan analysis method
To provide a glycan preparation method for preparing labeled glycans quickly from glycoproteins.SOLUTION: A glycan preparation method comprises: a releasing step in which a glycosidase is allowed to act on a glycoprotein immobilized on a solid phase in a container to obtain a released product containing glycans; and a labeling step in which a labeling reagent is added to the released product in the container to obtain a labeled product containing labeled glycans, wherein the glycoprotein is an antibody, the solid phase has on its surface a ligand selected from the group consisting of protein A, protein G, protein L, protein H, protein D, and protein Arp, and the labeling reagent comprises a reducer, a solution and at least one selected from the group consisting of 8-aminopyrene-1,3,6-trisulfonic acid, a sodium salt thereof, and 9-aminopyrene-1,4,6-trisulfonic acid.SELECTED DRAWING: None
Owner:SUMITOMO BAKELITE CO LTD
Protein l-binding polypeptide and use thereof
The purpose of the present invention is to provide a polypeptide capable of binding to protein L. Provided is a protein L-binding polypeptide comprising amino acid sequence 1, which is L1 sequence (such as the amino acid sequence represented by SEQ ID NO: 1) - antigen recognition sequence 1 - L2 sequence (such as the amino acid sequence represented by SEQ ID NO: 2) - antigen recognition sequence 2 - L3 sequence (such as the amino acid sequence represented by SEQ ID NO: 3) - antigen recognition sequence 3 - L4 sequence (such as the amino acid sequence represented by SEQ ID NO: 4).
Owner:NAT UNIV KYOTO INST OF TECH
Use of kosmotropes to enhance yield of an affinity chromatography purification step
The present disclosure provides methods and kits for purifying an antigen binding protein comprising a VL domain using a Protein L chromatography material which includes kosmotrope salts in the buffer background.
Owner:GENENTECH INC
Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof
ActiveUS12584116B2SsRNA viruses negative-senseViral antigen ingredientsPharmaceutical drugVeterinary Drugs
The invention relates to an attenuated variant of the Rift Valley Fever Virus (RVFV) with mutations in the amino acid sequence coded by segments L, M and S of RVFV RNA; a pharmaceutical or veterinary composition comprising same; an attenuated RVFV variant for use in the prevention of Rift Valley Fever, and a vaccine against Rift Valley Fever comprising the attenuated RVFV variant. Attenuated RVFV variants with the mutations Gly924Ser and Ala303Thr in protein L, and the Pro82Leu substitution in protein NSs, are also included.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Recombinant protein l protein with improved alkali resistance and use thereof
PCT designated stageWO2026057090A1Microorganism based processesPeptide preparation methodsEngineeringBiochemistry
The present application relates to the technical field of protein engineering, and specifically provides a recombinant Protein L protein with improved alkali resistance and use thereof. The recombinant Protein L protein of the present application has higher stability under alkaline conditions while maintaining high binding ability to immunoglobulins, thereby providing a more efficient and economical method for isolating immunoglobulins.
Owner:ACROBIOSYSTEMS AG
Method for producing chromatography carrier and chromatography carrier
InactiveJP2025154979AOther chemical processesSolid sorbent liquid separationCyclic etherChemical compound
To provide a chromatography carrier that has a large dynamic binding capacity for antibodies or fragments thereof and is resistant to leakage of protein ligands even when repeatedly used for antibody isolation.SOLUTION: A method for manufacturing a chromatography carrier comprises the following steps A-1 and B: (Step A-1) a step of immobilizing one or more ligands selected from Protein A, Protein G, Protein L, and their related substances onto porous particles; and (Step B) a step of reacting the porous particles with the ligands immobilized after the step A-1 with a compound having at least one ligand-reactive group selected from a group represented by -C(=O)-O-C(=O)-, a carbodiimide group, and a cyclic ether group.SELECTED DRAWING: None
Owner:JSR CORPORATION
Bispecific antibody platform
PendingCN121342981AHybrid immunoglobulinsImmunoglobulins against virusesComplementarity determining regionHeavy chain
The invention discloses a bispecific antibody platform, the platform is based on a recombinant light chain single domain antibody (VHHL), the platform is composed of a human IGKV3-20 light chain skeleton, and complementary determining regions CDR1, CDR2 and CDR3 of the skeleton are replaced by CDR of an antibody heavy chain derived from a human, a mouse, an alpaca or a camel. The VHHL retains the binding capacity with Protein L, and shows high stability, good solubility and strong affinity. Based on the VHHL, various forms of bispecific antibodies, including scFv, Fab and IgG forms, are constructed, and the VHHL serving as a targeting unit is combined with another targeting unit to form a bispecific molecule which is stable in structure and efficient in expression. The platform provides a more flexible choice for construction of a bi / multispecific antibody. For example, VHHLs on the two sides of the IgG form bispecific antibody can be combined with different antigens respectively and matched with an original heavy chain variable region of the IgG antibody to form a trispecific antibody.
Owner:FUDAN UNIVERSITY
PHOTOREACTIVE ANTIBODY-BINDING DOMAIN FOR SITE-SPECIFIC MODIFICATION OF THE ANTIGEN BINDING FRAGMENT (Fab) OF IgG AND IgM
PendingUS20260043807A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenDisease
Provided is an adapter comprising an antibody binding domain (AbBD) that specifically binds and crosslinks to an immunoglobulin Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, G32, Q35, S36, N46, G49, E50, K53 or L54 of SEQ ID NO: 1 or combinations thereof, and where the AbBD is photoreactive. Also provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region and / or to an immunoglobulin M (IgM) Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, E50, or L54 of SEQ ID NO: 1 or combinations thereof, where the AbBD is photoreactive. Provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region, where the AbBD is a variant of a Protein L C* domain and has an amino acid replacement / modification at G22 or T46 of SEQ ID NO: 2 or a combination thereof, wherein the AbBD is photo-reactive. Methods for using the AbBD for imaging, diagnosing and / or treating a disease are provided.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Recombinant Protein L protein with improved alkali resistance and application thereof
The invention relates to the technical field of protein engineering, and particularly provides a recombinant Protein L protein with improved alkali resistance and application thereof, the recombinant Protein L protein provided by the invention has higher stability under an alkaline condition, keeps high binding capacity to immune globulin, and provides a more efficient and economical way for separating the immune globulin.
Owner:ACROBIOSYSTEMS INC
Method for separating multispecific antibody
To provide a method that enables separation of a multispecific antibody contained in a sample.SOLUTION: A method for separating a multispecific antibody comprises the steps of: bringing a sample containing a multispecific antibody into contact with an antibody adsorbent comprising an insoluble carrier and an immunoglobulin-binding domain of Protein L (FpL) derived from a bacterium of the genus Finegoldia immobilized on the insoluble carrier, thereby adsorbing the antibody onto the adsorbent; and eluting the antibody adsorbed on the adsorbent using an eluent. Therein the eluent contains chloride ions, and the elution step elutes the antibody by a gradient that decreases a chloride ion concentration and a pH of the eluent, thereby solving the problem to be solved.SELECTED DRAWING: Figure 5
Owner:TOSOH CORP
Method for purifying eimeracil antibody
PendingCN121930354AImmunoglobulins against blood coagulation factorsHybrid immunoglobulinsAntiendomysial antibodiesBiochemistry
The invention relates to a purification method of an eimeracil antibody. According to the method, through protein L affinity chromatography, the eimeracil antibody is purified by utilizing the binding force difference between the target antibody / homopolymer and the filler, and compared with protein A affinity chromatography, the eimeracil antibody can be more effectively purified. Elution is carried out through a proper elution pH value, the homologous polymer can be further reduced, the purity of the eimeracil antibody can be effectively improved, the content of the homologous polymer can be reduced, and the method is simple in process and easy to operate.
Owner:QILU PHARMA CO LTD
Protein l-binding polypeptide and use thereof
To provide a polypeptide capable of binding to protein L.SOLUTION: A protein L-binding polypeptide comprising an amino acid sequence 1, that is, L1 sequence-antigen recognition sequence 1-A L2 sequence-antigen recognition sequence 2-A L3 sequence-antigen recognition sequence 3-A L4 sequence. The L1 sequence, L2 sequence, L3 sequence, and L4 sequence are each a specific amino acid sequence. The antigen-recognizing sequences 1, 2, and 3 may be an amino acid sequence encoding the light chain CDR1, an amino acid sequence encoding the light chain CDR2, and an amino acid sequence encoding the light chain CDR3, respectively, or an amino acid sequence encoding the heavy chain CDR1, an amino acid sequence encoding the heavy chain CDR2, and an amino acid sequence encoding the heavy chain CDR3, respectively.SELECTED DRAWING: None
Owner:NAT UNIV KYOTO INST OF TECH
Protein L for activation and expansion of chimeric antigen receptor-modified immune cells
ActiveUS12533414B2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorBiochemistry
Owner:FUJIFILM CELLULAR DYNAMICS INC
Immunoglobulin-binding protein production method
To provide a method that enables efficient production of a polypeptide containing at least an immunoglobulin-binding domain of Protein L (FpL) originating from Finegoldia bacteria.SOLUTION: A production method comprises the step of culturing a recombinant Escherichia coli containing a polynucleotide encoding a polypeptide including at least an immunoglobulin-binding domain of FpL and expressing the polypeptide, and the step of purifying the polypeptide from a culture of the Escherichia coli, wherein the step includes a purification step using an anion-exchange chromatography and a purification step using a hydrophobic chromatography, wherein the purification step using the hydrophobic chromatography includes a step of equilibrating a hydrophobic chromatography column, a step of adding a sample containing the polypeptide to the column, and a step of recovering the polypeptide, wherein at least one of a solution for equilibrating the column and the sample contains 0.4 mol / L-1.1 mol / L ammonium sulfate.SELECTED DRAWING: Figure 10
Owner:TOSOH CORP
Immunoglobulin-binding proteins
Disclosed is a protein which comprises an amino acid sequence derived from an immunoglobulin-binding domain of a protein L of a bacterium belonging to the genus Vincura, said amino acid sequence having at least one or more amino acid substitutions selected from the group consisting of (1) to (5) below. The protein has immunoglobulin binding activity: (1) an amino acid residue equivalent to tyrosine at position 42 of SEQ ID NO: 1 is substituted with histidine; (2) an amino acid residue equivalent to the lysine at position 22 of SEQ ID NO: 1 is substituted with glutamic acid; (3) an amino acid residue corresponding to the lysine at position 38 in SEQ ID NO: 1 is substituted with proline or aspartic acid; (4) an amino acid residue equivalent to tyrosine at position 42 in SEQ ID NO: 1 is substituted with tryptophan or phenylalanine; (5) The amino acid residue equivalent to the asparagine at position 44 in SEQ ID NO: 1 is substituted with proline.
Owner:TOSOH CORP
Artificial antigen presenting cells comprising protein L for expanding immune cells for immunotherapy
Disclosed herein are methods of expanding immune cells for immunotherapy and / or increasing the purity of a population of CAR T cells using artificial antigen presenting cells (aAPCs) having on their surface Protein L. The disclosed aAPCs can also secrete antibodies that bind molecules of the T cell inhibitory pathway. For example, anti-CD3 scFv on the surface of the aAPCs can bind and activate T cells, while anti-CD28 scFv and 4-1BBL on the surface of the aAPCs can provide dual co-stimulation for the T cells resulting in decreased levels of the markers CD25, TIM3, LAG3, and PD1. For example, blocking PD1 / PDL1 ligation can limit suppression that is mediated by the tumor microenvironment. This is a less costly and more efficient alternative to peripheral blood mononuclear cells (PBMCs) and cytokine treatments that result in better quality T cell for adoptive transfer back into patients.
Owner:H LEE MOFFITT CANCER CENT & RES
A recombinant protein L protein and a preparation method and application thereof
The application provides a recombinant Protein L protein and a preparation method and application thereof. The recombinant Protein L protein is a mutant of a Protein L protein domain B5, and is characterized in that the mutant is 1-6 repeat units, each repeat unit is obtained by mutation of an amino acid sequence of the B5 domain, and the mutation position is one or multiple positions of 18, 53 and 68 of the B5 domain. The application selects a strong alkali-resistant domain, the B5 domain of the Protein L protein as a template, and through mutation of amino acids, the protein has strong alkali resistance in a protein purification process, and the purification efficiency is improved.
Owner:PINGHU YOUPU BIOTECH CO LTD +1
Purification method of fasuximab
PendingCN122060072Ahigh purityHybrid immunoglobulinsImmunoglobulins against growth factorsBiochemistryPharmacology
The invention relates to a purification method of fasuximab. According to the method, through protein L affinity chromatography, the fasuximab is purified by utilizing the binding force difference between a target antibody / polymer impurity and a filler, and compared with a nano antibody ligand affinity medium, the fasuximab can be more effectively purified. In addition, compared with conventional low-pH elution, the antibody and the polymer can be effectively separated by increasing the elution pH, and the polymer is further reduced. According to the method disclosed by the invention, the purity of the fasuximab can be effectively improved, the polymer content is reduced, and the process is simple and easy to operate.
Owner:QILU PHARMA CO LTD
Artificial antigen presenting cells comprising protein l for expanding immune cells for immunotherapy
PendingUS20250388860A1Bacterial antigen ingredientsGenetically modified cellsPeripheral blood mononuclear cellMolecular binding
Disclosed herein are methods of expanding immune cells for immunotherapy and / or increasing the purity of a population of CAR T cells using artificial antigen presenting cells (aAPCs) having on their surface Protein L. The disclosed aAPCs can also secrete antibodies that bind molecules of the T cell inhibitory pathway. For example, anti-CD3 scFv on the surface of the aAPCs can bind and activate T cells, while anti-CD28 scFv and 4-1BBL on the surface of the aAPCs can provide dual co-stimulation for the T cells resulting in decreased levels of the markers CD25, TIM3, LAG3, and PD1. For example, blocking PD1 / PDL1 ligation can limit suppression that is mediated by the tumor microenvironment. This is a less costly and more efficient alternative to peripheral blood mononuclear cells (PBMCs) and cytokine treatments that result in better quality T cell for adoptive transfer back into patients.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC
PLAG-Tn5 fusion protein as well as preparation method and application thereof
The invention discloses a PLAG-Tn5 fusion protein as well as a preparation method and application thereof. According to the fusion protein, dominant immunoglobulin binding structural domains of Protein L, Protein A and Protein G are functionally fused with Tn5 transposase, so that IgG antibodies of various genus sources such as mice, rats and rabbits can be efficiently recognized in a broad-spectrum manner, and the problem of existing CUTamp is thoroughly solved; and the problems of poor antibody compatibility, need of using a second antibody, low signal-to-noise ratio and the like caused by insufficient PA / PG-Tn5 affinity in a Tag technology are solved. The invention also provides a low-cost and high-yield preparation method of the fusion protein and a matched preparation process of low-cost and high-efficiency carboxyl nucleic acid purification magnetic beads. The fusion protein and the magnetic beads jointly form the CUTamp which is low in cost, high in efficiency and high in sensitivity. A Tag research system is especially suitable for protein-DNA interaction research of precious low-amount clinical samples such as primary cells and PBMC, and popularization and clinical transformation of the technology are powerfully promoted.
Owner:KUNMING UNIV OF SCI & TECH